Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access


Venlafaxine in the treatment of depression in schizophrenia

Ayşen Esen-Danacı, Ömer Aydemir.

Objective:Depression in schizophrenia is associated with a poor
outcome, an increased risk of relapse and a high rate of suicide
therefore it must be treated carefully. Venlafaxine is a dual-action
serotonin and noradrenergic reuptake inhibitor and is effective in
treating depressive patients.

Method: In this study the efficacy and tolerability of venlafaxine is
evaluated in 8 schizophrenic patients with depression who used
venlafaxine adjunctive to atypical antipsychotics.

Results: The patients were assessed with Calgary Depression Scale
for Schizophrenia (CDSS), Scale for the Assessment of Positive and
Negative Symptoms (SAPS and SANS) at the beginning, 4th week and
8th week. At the end of 8th week of treatment, 2 patients were fully
remitted, the other 4 patients showed 80-90% improvement. Total
SAPS scores dropped 2 points whereas SANS scores were dropped
by 25%. No patients had an adverse event leading to an intervention.

Conclusion: Venlafaxine may be an effective and safe alternative in
the treatment of depression in schizophrenia.

Key words: Schizophrenia, depression, venlafaxine

Share this Article

American Journal of Physiology, Biochemistry and Pharmacology


ScopeMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.
Scopemed Buttons